Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
暂无分享,去创建一个
Christian Urban | Martin Zimmermann | Martin Stanulla | Andreas Feldges | Richard Ratei | Alfred Reiter | J. Harbott | M. Schrappe | G. Henze | K. Welte | C. Niemeyer | W. Ludwig | T. Klingebiel | F. Zintl | U. Bode | A. Möricke | H. Gadner | R. Beier | J. Boos | C. Urban | G. Mann | M. Stanulla | L. Löning | F. Niggli | A. Reiter | M. Zimmermann | Helmut Gadner | Wolf-Dieter Ludwig | Georg Mann | Martin Schrappe | Thomas Klingebiel | Karl Welte | Charlotte Niemeyer | D. Niethammer | R. Ratei | Günter Henze | Hansjörg Riehm | Jochen Harbott | H. Riehm | M. Dördelmann | Dietrich Niethammer | Rita Beier | Anja Möricke | Michael Dördelmann | Lutz Löning | Joachim Boos | Felix Niggli | Jörn-Dirk Beck | Felix Zintl | Udo Bode | Helmut Wehinger | J. Beck | H. Wehinger | A. Feldges | M. Zimmermann
[1] H. Sather,et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Jürgens,et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. , 1996, European journal of cancer.
[3] V. Poggi,et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. , 2002, Blood.
[4] J. Harbott,et al. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[5] P. Voûte,et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Hermans,et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996) , 2002, Leukemia.
[7] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[8] C C Bailey,et al. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials * , 1995, British journal of haematology.
[9] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[10] J. Stockman. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial , 2008 .
[11] G. Gustafsson,et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation , 2000, Leukemia.
[12] J. Harbott,et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.
[13] F. Behm,et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital , 2000, Leukemia.
[14] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[15] H. Cavé,et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. , 2000, Leukemia.
[16] J. Ritter,et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) , 1987 .
[17] G. Henze,et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. , 1990, Haematology and blood transfusion.
[18] R. Gelber,et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Martus,et al. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. , 2002, Medical and pediatric oncology.
[20] Maria Grazia Valsecchi,et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials , 1997 .
[21] F. Behm,et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Thiel,et al. Frequency and Clinical Significance of DNA Aneuploidy in Acute Leukemia , 1986, Annals of the New York Academy of Sciences.
[23] J. Harbott,et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. , 2000, Leukemia.
[24] D. Neuberg,et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.
[25] M. Schrappe,et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study , 2005, The Lancet.
[26] S. Lipsitz,et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Marsoni,et al. Treating childhood acute lymphoblastic leukaemia (ALL): summary of ten years' experience in Italy. ALL Steering Committee of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). , 1989, Medical and pediatric oncology.
[28] Y. Furukawa,et al. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro , 2002, Leukemia.
[29] M. Schrappe,et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Y. Hayashi,et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981–1995 , 2000, Leukemia.
[31] H. Sather,et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] G. Levitt,et al. Late anthracycline cardiotoxicity after childhood cancer , 2003, Cancer.
[33] F. Mandelli,et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982–1995 , 2000, Leukemia.
[34] J. Cayuela,et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] W. Hiddemann,et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.
[36] H. Sather,et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.
[37] A. Moghrabi,et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995) , 2000, Leukemia.
[38] N. Heerema,et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2002, Blood.
[39] S. Lipsitz,et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Borkhardt,et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. , 1996, Leukemia.
[41] A. Look,et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. Thiel,et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. , 1998, Blood.
[43] M. Schrappe,et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial , 2007, The Lancet.
[44] F. Uckun,et al. A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia. , 1999, Leukemia & lymphoma.
[45] A. Borkhardt,et al. Multiplex PCR – a rapid screening method for detection of gene rearrangements in childhood acute lymphoblastic leukemia , 1999, Annals of Hematology.
[46] J. Boos,et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia , 1997, British journal of haematology.
[47] G. Janka‐Schaub,et al. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92 , 2000, Leukemia.
[48] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[49] H. Conway. Lymphadenopathy in Brucellosis , 1949, British medical journal.
[50] N. Dastugue,et al. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[52] E. Cadman,et al. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. , 1979, The Journal of clinical investigation.
[53] J. Shuster,et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994 , 2000, Leukemia.
[54] D.,et al. Regression Models and Life-Tables , 2022 .
[55] M. Schrappe,et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] R. Jackson,et al. Synergistic and antagonistic interactions of methotrexate and 1-beta-D-arabinofuranosylcytosine in hepatoma cells. The modulating effect of purines. , 1981, Biochemical pharmacology.
[57] J. Chessells. Medical Research Council Leukaemia Trial-UKALL V: An Attempt to Reduce the Immunosuppressive Effects of Therapy in Childhood Acute Lymphoblastic Leukemia , 1986 .
[58] R. Pieters,et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.
[59] K. Tachibana,et al. Prophylactic cranial irradiation of acute lymphoblastic leukemia in childhood: Outcomes of late effects on pituitary function and growth in long‐term survivors , 2001, International journal of cancer.
[60] S. Richards,et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial , 2006, The Lancet.
[61] W. Hiddemann,et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.
[62] M. Borowitz,et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Effects of varying radiation schedule, cyclophosphamide treatment, and duration of treatment in acute lymphoblastic leukaemia. Report to the Medical Research Council by the Working Party on Leukaemia in Childhood. , 1978, British medical journal.
[64] B. Jereb,et al. LATE CARDIAC DAMAGE OF ANTHRACYCLINE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD , 2000, Pediatric hematology and oncology.
[65] Mark L. Greenberg,et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] M. Hudson,et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] W. Bleyer,et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995 , 2000, Leukemia.
[68] P. Duffner. Long-Term Effects of Radiation Therapy on Cognitive and Endocrine Function in Children With Leukemia and Brain Tumors , 2004, The neurologist.
[69] S. Richards,et al. Medical Research Council leukaemia trial--UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by the Working Party on Leukaemia in Childhood. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] J. Peto,et al. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood) , 1991, British journal of haematology.
[71] L. Freedman. Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.
[72] M. Schrappe,et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. , 1996, Blood.
[73] N. Heerema,et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.
[74] M. Schrappe,et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. , 2000, Blood.
[75] A. Berg,et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984–1991 , 2000, Leukemia.
[76] A. Borkhardt,et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. , 1997, Blood.
[77] C. Pui,et al. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children , 1996, The Lancet.
[78] S. Richards,et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial , 2005, British journal of haematology.
[79] S. Richards,et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997 , 2000, Leukemia.
[80] H. Cavé,et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report , 2000, Leukemia.